In the intricate realm of drug development, safeguarding auditory function emerges as a paramount concern. The threat of ototoxicity—a condition characterized by drug-induced damage to the ear—poses significant challenges in the pursuit of therapeutic advancements.
In a recent review article published in Frontiers in Molecular Neuroscience titled “Ototoxicity: A High Risk to Auditory Function That Needs to Be Monitored in Drug Development,” Cilcare & CBSET’s researchers illuminate the pressing need for vigilance in assessing and mitigating ototoxicity during the drug development process.
Edited by Peter S. Steyger, Creighton University, US, the publication delves into the multifaceted landscape of ototoxicity, encompassing its intricate mechanism of action, the spectrum of ototoxic drugs, and its profound epidemiological impact. By elucidating the underlying mechanisms through which ototoxic drugs induce damage to the auditory system, the authors underscore the importance of understanding the pathophysiology of drug-induced hearing loss.
Moreover, the article advocates for a comprehensive approach to monitoring ototoxicity during drug development, emphasizing the rationale behind proactive surveillance. With the recognition of ototoxicity as a significant risk factor, stakeholders are urged to integrate advanced screening technologies and predictive models into the development pipeline. These include innovative non-in vivo models such as organoids, cell-based assays, and cochlear explants, which offer valuable insights into drug-induced damage to the auditory system.
Furthermore, this review article underscores the importance of selecting appropriate in vivo models for ototoxicity assessment, taking into account species-specific differences in susceptibility to drug-induced hearing loss. By leveraging ototoxicity biomarkers and implementing robust monitoring protocols throughout the clinical phases, researchers can effectively identify and mitigate potential risks to auditory health.
Read the full article here: Link to the Publication
Related ototoxicity services available on Cilcare’s External Innovation section and CBSET auditory safety webpage
